{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:56:05Z","timestamp":1792684565308,"version":"4.5.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adeno-associated virus (AAV) gene therapy has the potential to functionally cure hemophilia B by restoring factor (F)IX concentrations into the normal range. Next-generation AAV therapies express a naturally occurring gain-of-function FIX variant, FIX-Padua (R338L-FIX), that increases FIX activity (FIX:C) by approximately eightfold compared with wild-type FIX (FIX-WT). Previous studies have shown that R338L-FIX activity varies dramatically across different clinical FIX:C assays, which complicates the monitoring and management of patients. To better understand mechanisms that contribute to R338L-FIX assay discrepancies, we characterized the performance of R338L-FIX in 13\u00a01-stage clotting assays (OSAs) and 2 chromogenic substrate assays (CSAs) in a global field study. This study produced the largest R338L-FIX assay dataset to date and confirmed that clinical FIX:C assay results vary over threefold. Both phospholipid and activating reagents play a role in OSA discrepancies. CSA generated the most divergent FIX:C results. Manipulation of FIX:C CSA kits demonstrated that specific activity gains for R338L-FIX were most profound at lower FIX:C concentrations and that these effects were enhanced during the early phases of FXa generation. Supplementing FX into CSA had the effect of dampening FIX-WT activity relative to R338L-FIX activity, suggesting that FX impairs WT tenase formation to a greater extent than R338L-FIX tenase. Our data describe the scale of R338L-FIX assay discrepancies and provide insights into the causative mechanisms that will help establish best practices for the measurement of R338L-FIX activity in patients after gene therapy.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007435","type":"journal-article","created":{"date-parts":[[2022,7,15]],"date-time":"2022-07-15T16:07:48Z","timestamp":1657901268000},"page":"458-467","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Differences in wild-type\u2013 and R338L-tenase complex formation are\u00a0at the root of R338L-factor IX assay discrepancies"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4593-0469","authenticated-orcid":false,"given":"Jonathan H.","family":"Foley","sequence":"first","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erald","family":"Shehu","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Riddell","sequence":"additional","affiliation":[{"name":"2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom"},{"name":"3Research Department of Haematology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Gray","sequence":"additional","affiliation":[{"name":"4Haemostasis section, Division of Biotherapeutics, National Institute for Biological Standards and Control, Hertfordshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Goodale","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I-Mei","family":"Yu","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-6965","authenticated-orcid":false,"given":"Dani\u00ebl","family":"Verhoef","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0555-5289","authenticated-orcid":false,"given":"John","family":"Little","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Shattock","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4790-1159","authenticated-orcid":false,"given":"Steve","family":"Kitchen","sequence":"additional","affiliation":[{"name":"5Department of Coagulation, Royal Hallamshire Hospital, Sheffield, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6690-8586","authenticated-orcid":false,"given":"Pratima","family":"Chowdary","sequence":"additional","affiliation":[{"name":"2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom"},{"name":"3Research Department of Haematology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Corbau","sequence":"additional","affiliation":[{"name":"1Freeline, Stevenage, Herts, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit C.","family":"Nathwani","sequence":"additional","affiliation":[{"name":"2Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free Hospital, London, United Kingdom"},{"name":"3Research Department of Haematology, University College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"5","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.transci.2019.08.010","article-title":"The evolution of recombinant factor replacement for hemophilia","volume":"58","author":"Sankar","year":"2019","journal-title":"Transfus Apheresis Sci"},{"issue":"1","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"3","key":"2023021422370957100_","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jim\u00e9nez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"issue":"25","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"Supplement 1","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood-2018-99-118334","article-title":"Adeno-associated mediated gene transfer for hemophilia B:8 year follow up and impact of removing empty viral particles on safety and efficacy of gene transfer","volume":"132","author":"Nathwani","year":"2018","journal-title":"Blood"},{"issue":"9","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2017-09-804419","article-title":"Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B","volume":"131","author":"Miesbach","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/bloodadvances.2019000811","article-title":"Etranacogene dezaparvovec (AMT-061 phase 2b): normal\/near normal FIX activity and bleed cessation in hemophilia B","volume":"3","author":"Von Drygalski","year":"2019","journal-title":"Blood Adv"},{"issue":"S2","key":"2023021422370957100_","first-page":"1","article-title":"A\u00a0novel adeno associated virus (AAV) gene therapy (FLT180a) achieves normal FIX activity levels in severe hemophilia B (HB) patients (B-AMAZE Study)","volume":"4","author":"Chowdary","year":"2020","journal-title":"Res. Pract. Thromb. Haemost"},{"issue":"17","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtm.2018.12.007","article-title":"Protein-engineered coagulation factors for hemophilia gene therapy","volume":"12","author":"Samelson-Jones","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"14","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"e128683","DOI":"10.1172\/jci.insight.128683","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"2023021422370957100_","first-page":"932","article-title":"Comparative field study: impact of laboratory assay variability on the assessment of recombinant factor IX Fc fusion protein (rFIXFc) activity","volume":"112","author":"Sommer","year":"2014","journal-title":"Thromb Haemost"},{"issue":"7","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/jth.13348","article-title":"Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study","volume":"14","author":"Bowyer","year":"2016","journal-title":"J\u00a0Thromb Haemost"},{"issue":"S1","key":"2023021422370957100_","article-title":"FLT180a: Next generation AAV vector for haemophilia B - long term, follow-up and in-depth analysis of transgenic FIX using one-stage, chromogenic and global assays","volume":"3","author":"Chowdary","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"Robinson","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"issue":"1","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1365-2516.2008.01826.x","article-title":"Potency and mass of factor VIII in FVIII products","volume":"15","author":"Butenas","year":"2009","journal-title":"Haemophilia"},{"issue":"7","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1111\/j.1538-7836.2010.03899.x","article-title":"Coagulation procofactor activation by factor XIa","volume":"8","author":"Whelihan","year":"2010","journal-title":"J\u00a0Thromb Haemost"},{"issue":"3","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1160\/TH14-06-0515","article-title":"Polyphosphate accelerates factor V activation by factor XIa","volume":"113","author":"Choi","year":"2015","journal-title":"Thromb Haemost"},{"issue":"14","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1182\/blood-2017-02-767079","article-title":"Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex","volume":"130","author":"Kamikubo","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s12185-019-02611-3","article-title":"Potential role of activated factor VIII (FVIIIa) in FVIIa\/tissue factor-dependent FXa generation in initiation phase of blood coagulation","volume":"109","author":"Furukawa","year":"2019","journal-title":"Int J Hematol"},{"issue":"1","key":"2023021422370957100_","doi-asserted-by":"crossref","first-page":"15449","DOI":"10.1038\/s41598-019-51984-2","article-title":"Effects of codon optimization on coagulation factor IX translation and structure: implications for protein and gene therapies","volume":"9","author":"Alexaki","year":"2019","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/458\/2033390\/blooda_adv-2022-007435-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/3\/458\/2033390\/blooda_adv-2022-007435-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T16:37:12Z","timestamp":1700843832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/3\/458\/485933\/Differences-in-wild-type-and-R338L-tenase-complex"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,2,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007435","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]}}}